Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas

Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas

Background. Epidermal growth factor receptor is overexpressed in most pediatric high-grade gliomas (HGG). Since erlotinib had shown activity in adults with HGG, we conducted a phase II trial of erlotinib and local radiotherapy in children with newly diagnosed HGG. <br/>Methods. Following maxim...

Full description

Bibliographic Details
Main Authors:	Ibrahim eQaddoumi, Mehmet eKocak, Atmaram S. Pai-Panandiker, Gregory T. Armstrong, Cynthia eWetmore, John R. Crawford, Tong eLin, James M Boyett, Larry E. Kun, Fredrick A. Boop, Thomas E. Merchant, David W Ellison, Amar eGajjar, Alberto eBroniscer
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2014-04-01
Series:	Frontiers in Oncology
Subjects:	Radiotherapy pediatric epidermal growth factor receptor erlotinib high-grade glioma phase II
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00067/full

Similar Items

Four Cases of Interstitial Lung Disease Induced by Erlotinib  and A Review of the Literatures
by: Xiaoling WU, et al.
Published: (2012-08-01)

Severe cicatricial alopecia as a rare cutaneous side effect due to erlotinib – case report
by: Magdalena Żychowska, et al.
Published: (2016-10-01)

Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma
by: Chenwei Wang, et al.
Published: (2021-03-01)

Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
by: Abdul-Rahman Jazieh, et al.
Published: (2013-01-01)

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer
by: Renhua GUO, et al.
Published: (2009-12-01)

Molecular Mechanism of Erlotinib Resistance in Epidermal Growth Factor Receptor  Mutant Non-small cell Lung Cancer Cell Line H1650
by: Ruili HAN, et al.
Published: (2012-12-01)

Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases
by: Donato Callegaro-Filho, et al.
Published: (2014-01-01)

The ways of erlotinib resistance overcoming in treatment of patients with eGFr mutated nsClC
by: S V Orlov
Published: (2013-12-01)

Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation
by: Liu J, et al.
Published: (2016-02-01)

Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01)

Sustained Response of a Clivus Chordoma to Erlotinib after Imatinib Failure
by: Aline Houessinon, et al.
Published: (2015-01-01)

Real-time molecular optical micro-imaging of EGFR mutations using a fluorescent erlotinib based tracer
by: Maxime Patout, et al.
Published: (2019-01-01)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
by: Christina Demuth, et al.
Published: (2018-02-01)

Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect?
by: Maddalena Zippi, et al.
Published: (2016-08-01)

Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer
by: Yilong WU, et al.
Published: (2009-05-01)

Modified Synthesis of Erlotinib Hydrochloride
by: Leila Barghi, et al.
Published: (2012-06-01)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015-09-01)

Erlotinib Treatment in a Case of Lung Adenocarcinoma Mimicking Interstitial Lung Disease
by: Şenay Yılmaz, et al.
Published: (2017-04-01)

Treatment tactics of non-small-cell lung cancer with erlotinib: literature review and description of a clinical case
by: E. I. Borisova, et al.
Published: (2019-12-01)

Bilateral acute simultaneous onset anterior uveitis presumed secondary to erlotinib: A report of two cases
by: Kendra A. Klein, et al.
Published: (2017-06-01)

Development and Application of an HPLC Method for Erlotinib Protein Binding Studies
by: Soheila Bolandnazar, et al.
Published: (2013-08-01)

A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
by: Preenumol Thomas, et al.
Published: (2019-01-01)

Erlotinib resistance in Lung Cancer: Current Progress and Future Perspectives
by: Joy eTang, et al.
Published: (2013-02-01)

Spontaneous Healing of Corneal Perforation after Temporary Discontinuation of Erlotinib Treatment
by: Naoyuki Morishige, et al.
Published: (2014-01-01)

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01)

Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
by: Haiqing YUAN, et al.
Published: (2009-07-01)

Clinical research progress in Erlotinib treatment for hepatocellular carcinoma
by: GAO Fan
Published: (2015-06-01)

OCTA analysis of the effect of Erlotinib on corneal thickness in mice
by: Qing Yuan, et al.
Published: (2019-08-01)

Acute Generalized Exanthematous Pustulosis Induced by Erlotinib (Tarceva) with Superimposed Staphylococcus aureus Skin Infection in a Pancreatic Cancer Patient: A Case Report
by: Egbert Liquete, et al.
Published: (2012-05-01)

Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
by: Katsuhiro Masago, et al.
Published: (2010-04-01)

A Systematic Review of Erlotinib for Advanced Non-small Cell Lung Cancer
by: Jinhui TIAN, et al.
Published: (2009-12-01)

The Analysis of Erlotinib on Brain Metastases in Patients with Non-small-cell Lung Cancer
by: Baohui HAN, et al.
Published: (2009-12-01)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
by: Cavazzoni Andrea, et al.
Published: (2012-12-01)

A Retrospective Analysis of Erlotinib and TP/GP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer
by: Yongjuan WU, et al.
Published: (2009-12-01)

A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
by: Nawazish A. Khan, et al.
Published: (2014-07-01)

Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer and COPD
by: Huiling ZHANG, et al.
Published: (2009-12-01)

A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer
by: Mingzhi LI, et al.
Published: (2009-12-01)

The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy
by: Demiray A, et al.
Published: (2018-12-01)

Erlotinib-associated severe bilateral recalcitrant keratouveitis after corneal EDTA chelation
by: Zimei Zhou, et al.
Published: (2016-12-01)

How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01)